卡博替尼治疗未经局部预处理的肾细胞癌脑转移:CABRAMET II期试验结果
CABRAMET是一项多中心开放标签II期试验,评估VEGFR酪氨酸激酶抑制剂卡博替尼在未经局部预处理的肾细胞癌脑转移患者中的疗效。研究纳入26例患者,主要终点为脑转移6个月无进展率(6m-BM-PFR),结果显示6m-BM-PFR为56%,脑转移客观缓解率(ORR)为61.5%,中位脑转移无进展生存期(BM-PFS)为10.7个月,中位总生存期(OS)为15.0个月。
要点
- 卡博替尼在未经局部预处理的RCC脑转移患者中6个月脑转移无进展率为56%。
- 研究者评估的脑转移客观缓解率为61.5%(16/26),中位脑转移缓解持续时间未达到。
- 一线治疗脑转移ORR达86%,既往免疫治疗者67%,既往TKI治疗者40%。
核心结论
- CABRAMET是首个前瞻性评估卡博替尼在未经局部预处理的RCC脑转移患者中的试验,显示其在部分患者中具有持久疗效和耐受性。
研究设计与样本
- 多中心开放标签II期试验,纳入RCC脑转移患者,既往系统治疗少于3线且排除卡博替尼。
- 患者接受卡博替尼60mg/天口服,根据毒性调整剂量。
- 主要终点为脑转移6个月无进展率(6m-BM-PFR),次要终点包括脑转移ORR、缓解持续时间、颅外ORR、BM-PFS、整体PFS、OS和安全性。
主要发现
- 共纳入26例患者,中位随访38.8个月(范围28.3-52.7个月)。
- 中心评估的6m-BM-PFR为56%(单侧95%CI 37.9-)。
- 研究者评估的脑转移部分缓解为16/26例(BM ORR 61.5%)。
- 中位脑转移缓解持续时间未达到,24个月时58.3%(95%CI 29.3-78.9%)的患者无事件。
- 中位BM-PFS为10.7个月(95%CI 5.4-NR),中位整体PFS为8.1个月(95%CI 4-11.9),中位OS为15.0个月(95%CI 9.3-35.0)。
关键数值与推荐
- 一线治疗脑转移ORR为86%,既往免疫治疗者67%,既往TKI治疗者40%。
临床怎么用
- 卡博替尼可作为未经局部预处理的RCC脑转移患者的系统治疗选择之一,尤其在一线或既往免疫治疗失败后。
局限性
- 样本量较小(26例),随访时间有限,部分终点置信区间较宽。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The phase II trial CABRAMET evaluates the efficacy of the VEGFR tyrosine kinase inhibitor (TKI) cabozantinib in patients with non-locally pretreated brain metastases (BM) from renal cell carcinoma (RCC). Faced with historical challenges in treating BM in RCC, this study aimed to provide prospective data on systemic treatment outcomes. PATIENTS AND METHODS: This multicenter open-label trial included RCC patients with BM with less than three prior systemic treatments excluding cabozantinib. Eligible patients received 60mg/day oral cabozantinib with dose adjustments for toxicity. The primary endpoint was the 6-month progression-free rate in brain metastases (6m-BM-PFR). The main secondary endpoints included BM objective response rate (ORR) and response duration in BM, extra-cranial ORR, BM and overall progression-free survival (PFS), overall survival (OS), and safety. RESULTS: The study enrolled 26 patients, with a median follow-up of 38.8 months (range 28.3-52.7 months). The 6m-BM-PFR was 56% (unilateral 95%CI 37.9-) by central review. BM partial responses were achieved in 16/26 patients (BM ORR of 61.5%) by investigator assessment. The median BM response duration was not reached and 58.3% (95%CI 29.3-78.9%) of the patients were event-free at 24 months. The median BM-PFS was 10.7 (95%CI 5.4-NR) months, and the median overall PFS was 8.1 (95%CI 4-11.9) months. The median OS was 15.0 (95%CI 9.3-35.0) months. Cabozantinib exhibited significant efficacy as first-line treatment with BM ORR of 86%, 67% in patients with prior immunotherapy, 40% in patients previously treated with TKI. CONCLUSION: The CABRAMET trial is the first to prospectively assess cabozantinib in the challenging population of non-locally pretreated brain metastases from RCC, highlighting its prolonged efficacy and tolerability in selected patients with BM. CLINICAL TRIAL REGISTRATION: NCT03967522.
引用
- Negrier S, Mourey L, Dalban C, et al. Cabozantinib in patients with non-locally pretreated brain metastases from renal cell carcinoma: Results of the multicenter phase II trial CABRAMET. Eur J Cancer. 2026. PMID: 41946178. doi:10.1016/j.ejca.2026.116712
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。